Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease‑modifying antirheumatic drugs: SPIRIT‑P1 and SPIRIT‑P2 3‑year results
Clin Rheumatol. 2022 doi: 10.1007/s10067-022-06218-8
In this investigation ixekizumab showed sustained efficacy in PsA therapy for up to three years in both monotherapy and combination with MTX or a csDMARD. Here, investigators set out to evaluate the three-year efficacy and safety of ixekizumab with and without csDMARD use in patients with active PsA.
To do this they pooled date from two related studies comparing ixekizumab, namely the SPRIT-P1 and SPIRIT-P2 studies.
Safety data also provides further information on the use of ixekizumab. Similar safety and immunogenicity profiles were observed across both mono- and concomitant therapy groups, supporting the use of concomitant MTX or csDMARDs in the treatment of active PsA.
Keywords:
